Profile data is unavailable for this security.
About the company
Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.
- Revenue in GBP (TTM)0.00
- Net income in GBP-17.91m
- Incorporated2006
- Employees37.00
- LocationFaron Pharmaceuticals OyJoukahaisenkatu 6TURKU 20520FinlandFIN
- Phone+358 24695151
- Fax+358 24695152
- Websitehttps://www.faron.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4X Discovery Holdings PLC | 5.71m | -4.72m | 58.68m | 46.00 | -- | 3.86 | -- | 10.28 | -0.0207 | -0.0207 | 0.0251 | 0.0664 | 0.3055 | -- | 9.62 | 124,087.00 | -25.27 | -60.05 | -27.28 | -68.53 | 97.39 | 99.28 | -82.71 | -237.08 | -- | -493.00 | 0.0192 | -- | -- | 82.46 | 50.65 | -- | -13.79 | -- |
| Eco Animal Health Group Plc | 101.55m | 5.57m | 82.28m | 207.00 | 14.76 | 0.9842 | 5.80 | 0.8103 | 0.0823 | 0.0823 | 1.50 | 1.23 | 0.9131 | 2.17 | 3.60 | 490,584.50 | 11.31 | 10.55 | 15.40 | 13.14 | 49.93 | 48.53 | 12.38 | 14.62 | 2.57 | -- | 0.0145 | 47.19 | 46.46 | 17.51 | 109.45 | 6.21 | -30.72 | -29.40 |
| Futura Medical plc. | 0.00 | -4.96m | 99.33m | 11.00 | -- | 10.21 | -- | -- | -0.018 | -0.018 | 0.00 | 0.0339 | 0.00 | -- | -- | 0.00 | -73.87 | -65.78 | -93.73 | -86.83 | -- | -- | -- | -6,607.25 | -- | -- | 0.00 | -- | -- | -- | -105.85 | -- | 123.78 | -- |
| e-Therapeutics plc | 477.00k | -8.07m | 108.33m | 32.00 | -- | 3.87 | -- | 227.10 | -0.0169 | -0.0169 | 0.001 | 0.0544 | 0.0217 | -- | 3.31 | 14,906.25 | -36.62 | -37.71 | -38.29 | -40.40 | 100.00 | 100.00 | -1,691.82 | -1,812.91 | -- | -- | 0.0239 | -- | 50.47 | -- | -119.06 | -- | 42.31 | -- |
| Scancell Holdings Plc | 0.00 | -8.41m | 109.04m | 25.00 | -- | 4.81 | -- | -- | -0.0105 | -0.0105 | 0.00 | 0.0278 | 0.00 | -- | -- | 0.00 | -21.98 | -48.49 | -24.78 | -52.14 | -- | -- | -- | -- | -- | -- | 0.2598 | -- | -- | -- | -181.09 | -- | -- | -- |
| Faron Pharmaceuticals Oy | 0.00 | -17.91m | 112.02m | 37.00 | -- | 43.78 | -- | -- | -0.3531 | -0.3531 | 0.00 | 0.0463 | 0.00 | -- | -- | 0.00 | -196.84 | -165.50 | -539.12 | -391.61 | -- | -- | -- | -487,178.90 | -- | -248.33 | 0.5486 | -- | -- | -- | -25.16 | -- | 38.80 | -- |
| Sareum Holdings Plc | 0.00 | -1.81m | 129.33m | 6.00 | -- | 22.77 | -- | -- | -0.0273 | -0.0273 | 0.00 | 0.0834 | 0.00 | -- | -- | 0.00 | -48.39 | -49.67 | -51.44 | -54.40 | -- | -- | -- | -10,610.04 | -- | -- | 0.00 | -- | -100.00 | -- | -52.18 | -- | -- | -- |
| Creo Medical Group PLC | 25.16m | -24.60m | 134.25m | 290.00 | -- | 1.83 | -- | 5.34 | -0.1487 | -0.1487 | 0.153 | 0.4049 | 0.2606 | 1.77 | 5.34 | 86,762.07 | -25.48 | -- | -31.67 | -- | 46.04 | -- | -97.75 | -- | 2.67 | -69.23 | 0.1259 | -- | 166.85 | -- | -21.06 | -- | -- | -- |
| Circassia Group PLC | 27.90m | 2.30m | 147.06m | 128.00 | 79.66 | 2.01 | 21.63 | 5.27 | 0.0044 | 0.0075 | 0.064 | 0.1742 | 0.2945 | 2.66 | 2.45 | 217,968.80 | 2.43 | -11.69 | 2.80 | -13.99 | 68.10 | 76.19 | 8.24 | -81.99 | 1.58 | -- | 0.0191 | -- | 16.74 | 3.85 | 108.58 | -- | -22.16 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Mar 2022 | 2.63m | 4.76% |
| Skandinaviska Enskilda Banken AB (Denmark)as of 31 Mar 2022 | 2.22m | 4.02% |
| Rhenman & Partners Asset Management ABas of 30 Jun 2021 | 500.00k | 0.91% |
| Canaccord Genuity Wealth Ltd.as of 31 Mar 2022 | 195.99k | 0.36% |
| Aktia Varainhoito Oyas of 31 Oct 2021 | 117.37k | 0.21% |
| Henderson Global Investors Ltd.as of 30 Jun 2022 | 100.00k | 0.18% |
| Sp-Fund Management Co. Ltd.as of 29 Jul 2022 | 50.42k | 0.09% |
| BG Fund Management Luxembourg SAas of 30 Jun 2022 | 31.74k | 0.06% |
